Prandin Use Code Case Taken Up By High Court

Law360, New York (June 27, 2011, 12:42 PM EDT) -- The U.S. Supreme Court on Monday agreed to review Novo Nordisk AS' win in a patent dispute over diabetes drug Prandin, a decision generic-drug makers claim has made it easier for pharmaceutical companies to avoid competition.

The high court granted Caraco Pharmaceutical Laboratories Ltd.'s petition for certiorari in a long-running patent fight stemming from the company's bid to launch a generic version of Prandin.

Caraco is seeking to overturn a ruling for Novo by the Federal Circuit, holding that the counterclaim provision of the Hatch-Waxman Act...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.